Latest & greatest articles for cardiovascular disease

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on cardiovascular disease or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on cardiovascular disease and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for cardiovascular disease

1. Alirocumab (Praluent) - In adults with established atherosclerotic cardiovascular disease to reduce cardiovascular risk by lowering LDL-C levels

Alirocumab (Praluent) - In adults with established atherosclerotic cardiovascular disease to reduce cardiovascular risk by lowering LDL-C levels Published 10 June 2019 Statement of advice SMC2201 alirocumab 75mg / 150mg solution for injection in pre-filled pen (Praluent®) Sanofi-Aventis Ltd 10 May 2019 ADVICE: in the absence of a submission from the holder of the marketing authorisation alirocumab (Praluent®) is not recommended for use within NHSScotland. Indication under review: In adults (...) with established atherosclerotic cardiovascular disease to reduce cardiovascular risk by lowering LDL-C levels, as an adjunct to correction of other risk factors: ? in combination with the maximum tolerated dose of a statin with or without other lipid- lowering therapies or, ? alone or in combination with other lipid-lowering therapies in patients who are statin- intolerant, or for whom a statin is contraindicated. The holder of the marketing authorisation has not made a submission to SMC regarding

2019 Scottish Medicines Consortium

2. Cardiovascular disease prevention: applying All Our Health

Cardiovascular disease prevention: applying All Our Health Cardiovascular disease prevention: applying All Our Health - GOV.UK GOV.UK uses cookies to make the site simpler. Accept cookies You’ve accepted all cookies. You can at any time. Hide Search Guidance Cardiovascular disease prevention: applying All Our Health Updated 17 June 2019 Contents © Crown copyright 2019 This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view (...) this licence, visit or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: . Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned. This publication is available at https://www.gov.uk/government/publications/cardiovascular-disease-prevention-applying-all-our-health/cardiovascular-disease-prevention-applying-all-our-health Why promote is now available to use. Public Health England

2019 Public Health England

3. Effect of Aclidinium Bromide on Major Cardiovascular Events and Exacerbations in High-Risk Patients With Chronic Obstructive Pulmonary Disease: The ASCENT-COPD Randomized Clinical Trial. (PubMed)

Effect of Aclidinium Bromide on Major Cardiovascular Events and Exacerbations in High-Risk Patients With Chronic Obstructive Pulmonary Disease: The ASCENT-COPD Randomized Clinical Trial. There is concern that long-acting muscarinic antagonists increase cardiovascular morbidity or mortality in patients with chronic obstructive pulmonary disease (COPD).To determine the cardiovascular safety (noninferiority) and efficacy (superiority) of aclidinium bromide, 400 μg twice daily, in patients (...) with COPD and cardiovascular disease or risk factors.Multicenter, randomized, placebo-controlled, double-blind, parallel-design study conducted at 522 sites in North America. A total of 3630 patients with moderate to very severe COPD and either a history of cardiovascular disease or at least 2 atherothrombotic risk factors were randomized; follow-up occurred for up to 3 years until at least 122 major adverse cardiovascular events (MACE) occurred. The first patient was enrolled on October 16, 2013

2019 JAMA

4. Bioresorbable Stents in cardiovascular indications (coronary artery disease)

Bioresorbable Stents in cardiovascular indications (coronary artery disease) Dec2015 © EUnetHTA, 2015. Reproduction is authorised provided EUnetHTA is explicitly acknowledged 1 EUnetHTA Joint Action 3 WP4 Version 1.4, 28 January 2019 Rapid assessment of other technologies using the HTA Core Model ® for Rapid Relative Effectiveness Assessment BIORESORBABLE STENTS FOR THE TREATMENT OF CARDIOVASCULAR INDICATIONS (CORONARY ARTERY DISEASE) Project ID: OTCA16 Bioresorbable stents for cardiovascular (...) and Confidentiality Undertaking of Interest (DOICU) statement form. How to cite this assessment Please cite this assessment as follows: IAMEV, SNSPMPDSB et al. Bioresorbable stents for the treatment of cardiovascular indications (coronary artery disease). Rapid assessment of other health technologies using the HTA Core Model for Rapid Relative Effectiveness Assessment. EUnetHTA Project ID: OTCA16. 2019. Bioresorbable stents for cardiovascular indications Version 1.4, 28 January 2019 EUnetHTA Joint Action 3 WP4 4

2019 EUnetHTA

5. The Effects of Long-term CPAP on Weight Change in Patients With Comorbid OSA and Cardiovascular Disease: Data From the SAVE Trial (Full text)

The Effects of Long-term CPAP on Weight Change in Patients With Comorbid OSA and Cardiovascular Disease: Data From the SAVE Trial Although recent evidence suggests that OSA treatment may cause weight gain, the long-term effects of CPAP on weight are not well established.This study was a post hoc analysis of the Sleep Apnea Cardiovascular Endpoints (SAVE) study, a multicenter, randomized trial of CPAP plus standard care vs standard care alone in adults with a history of cardiac (...) subjects without CPAP (mean difference, 0.38 kg [95% CI, 0.04 to 0.73]; P = .031), there were no between-group differences in other anthropometric variables, nor were there any differences between female high CPAP adherers and matched control subjects.Long-term CPAP use in patients with comorbid OSA and cardiovascular disease does not result in clinically significant weight change.ClinicalTrials.gov; No.: NCT00738179; URL: www.clinicaltrials.gov.Copyright © 2018 American College of Chest Physicians

2019 EvidenceUpdates PubMed

6. Interim: Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer

Interim: Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer 1 Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer Interim Guidance from the Kaiser Permanente National Integrated Cardiovascular Health (ICVH) Work Group October 5, 2018 Three randomized clinical trials (ARRIVE 1 , ASCEND 2 , and ASPREE 3 ) recently published results on aspirin use in patients without known Atherosclerotic Cardiovascular Disease (ASCVD). The studies looked at benefits including (...) and Hispanics in the United States) to 100 mg aspirin or placebo. The primary outcome was a composite of death, dementia, or persistent physical disability. Secondary outcomes included major hemorrhage and cardiovascular disease (defined as fatal coronary heart disease, nonfatal myocardial infarction, fatal or nonfatal stroke, or hospitalization for heart failure). The rate of cardiovascular disease was 10.7 events per 1000 person-years in the aspirin group vs.11.3 events per 1000 person-years

2019 Kaiser Permanente National Guideline Program

7. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive summary (Full text)

2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive summary 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary | Circulation Search Hello Guest! Login to your account Email Password Keep me logged in Search April 2019 April 2019 April 2019 April 2019 March 2019 March 2019 March 2019 March 2019 March 2019 February 2019 February 2019 February 2019 February 2019 January 2019 January 2019 January 2019 January 2019 January (...) 2019 This site uses cookies. By continuing to browse this site you are agreeing to our use of cookies. Free Access article Share on Jump to Free Access article 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines , PhD, MSPH, FAHA, Co-Chair , MD, FACC, FAHA, Co-Chair , MD, MPH, FAHA , Esq , MD, MS, FACC, FAHA , PhD, RN , PhD, RN, ANP, FAHA

2019 American Heart Association PubMed

8. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease

2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease Arnett et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease Page 1 of 98 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation, the American Geriatrics Society, the American (...) ://ahajournals.org by on April 25, 2019Arnett et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease Page 2 of 98 The American Heart Association requests that this document be cited as follows: Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, Himmelfarb CD, Khera A, Lloyd-Jones D, McEvoy JW, Michos ED, Miedema MD, Muñoz D, Smith SC Jr, Virani SS, Williams KA Sr, Yeboah J, Ziaeian B. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease

2019 American Heart Association

9. Mendelian Randomization Study of <i>ACLY</i> and Cardiovascular Disease. (PubMed)

Mendelian Randomization Study of ACLY and Cardiovascular Disease. ATP citrate lyase is an enzyme in the cholesterol-biosynthesis pathway upstream of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR), the target of statins. Whether the genetic inhibition of ATP citrate lyase is associated with deleterious outcomes and whether it has the same effect, per unit decrease in the low-density lipoprotein (LDL) cholesterol level, as the genetic inhibition of HMGCR is unclear.We constructed (...) lifelong genetic inhibition of HMGCR was associated with an increased risk of cancer.Genetic variants that mimic the effect of ATP citrate lyase inhibitors and statins appeared to lower plasma LDL cholesterol levels by the same mechanism of action and were associated with similar effects on the risk of cardiovascular disease per unit decrease in the LDL cholesterol level. (Funded by Esperion Therapeutics and others.).Copyright © 2019 Massachusetts Medical Society.

2019 NEJM

10. Mediterranean-style diet for the primary and secondary prevention of cardiovascular disease. (PubMed)

Mediterranean-style diet for the primary and secondary prevention of cardiovascular disease. The Seven Countries study in the 1960s showed that populations in the Mediterranean region experienced lower coronary heart disease (CHD) mortality probably as a result of different dietary patterns. Later observational studies have confirmed the benefits of adherence to a Mediterranean dietary pattern on cardiovascular disease (CVD) risk factors but clinical trial evidence is more limited.To determine

2019 Cochrane

11. Transition from metabolically benign to metabolically unhealthy obesity and 10-year cardiovascular disease incidence: the ATTICA cohort study

Transition from metabolically benign to metabolically unhealthy obesity and 10-year cardiovascular disease incidence: the ATTICA cohort study Metabolically benign obesity remains a scientific field of considerable debate. The aim of the present work was to evaluate whether metabolically healthy obese (MHO) status is a transient condition which propagates 10-year cardiovascular disease (CVD) onset.A prospective longitudinal study was conducted during 2001-2012, the ATTICA study studying 1514

2019 EvidenceUpdates

12. Predicting Bleeding Risk to Guide Aspirin Use for the Primary Prevention of Cardiovascular Disease: A Cohort Study. (PubMed)

Predicting Bleeding Risk to Guide Aspirin Use for the Primary Prevention of Cardiovascular Disease: A Cohort Study. Many prognostic models for cardiovascular risk can be used to estimate aspirin's absolute benefits, but few bleeding risk models are available to estimate its likely harms.To develop prognostic bleeding risk models among persons in whom aspirin might be considered for the primary prevention of cardiovascular disease (CVD).Prospective cohort study.New Zealand primary care.The study (...) models included the following predictors: demographic characteristics (age, ethnicity, and socioeconomic deprivation), clinical measurements (systolic blood pressure and ratio of total-high-density lipoprotein cholesterol), family history of premature CVD, medical history (smoking, diabetes, bleeding, peptic ulcer disease, cancer, chronic liver disease, chronic pancreatitis, or alcohol-related conditions), and medication use (nonsteroidal anti-inflammatory agents, corticosteroids, and selective

2019 Annals of Internal Medicine

13. Fish oil supplements do not reduce cardiovascular deaths in people with diabetes without existing vascular disease

Fish oil supplements do not reduce cardiovascular deaths in people with diabetes without existing vascular disease Fish oil supplements lack heart benefits in diabetes without existing vascular disease Discover Portal Discover Portal Fish oil supplements do not reduce cardiovascular deaths in people with diabetes without existing vascular disease Published on 4 December 2018 doi: Omega-3 fatty acid supplements make no difference to cardiovascular outcomes in people with diabetes but without (...) established cardiovascular disease. Serious vascular events like heart attack, stroke or deaths from these occurred in about 10% of people regardless of whether they took daily omega-3 or placebo capsules for seven years. The ASCEND study is a large UK trial assessing primary cardiovascular prevention for people with any type of diabetes. A companion publication assesses the use of aspirin. The results are consistent with a recent large Cochrane review assessing omega-3 fatty acids in any population

2019 NIHR Dissemination Centre

14. The effect of glycemic control on cardiovascular disease in individuals with type 2 diabetes with pre-existing cardiovascular disease - a systematic review and meta-analysis

The effect of glycemic control on cardiovascular disease in individuals with type 2 diabetes with pre-existing cardiovascular disease - a systematic review and meta-analysis The role of intensive glucose control in people with type 2 diabetes and pre-existing cardiovascular disease (CVD) is controversial. The aim of this systematic review and meta-analysis was to determine in a subset of people with type 2 diabetes and pre-existing CVD, the CV effect of intensive glucose control versus standard

2019 EvidenceUpdates

15. Aquatic-based exercise for individuals with cardiovascular diseases: a systematic review and meta-analysis of randomized controlled trials

Aquatic-based exercise for individuals with cardiovascular diseases: a systematic review and meta-analysis of randomized controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration (...) of index ischemia (linear); stem cell dose (linear); blinding of outcome assessment reported (stratified yes vs no). For stratified analyses, a minimum number of 8 studies per subgroup is required. ">Subgroup analyses A sensitivity analysis is conducted to assess the impact of decisions taken in the review process on the meta-analysis outcome. These decisions may have been made in various stages of the review, e.g. the decision to exclude certain disease models, the decision to pool certain units

2019 PROSPERO

16. What is the association between statins, when prescribed for primary or secondary prevention of cardiovascular disease, and key outcomes for community dwelling older adults living with frailty?

What is the association between statins, when prescribed for primary or secondary prevention of cardiovascular disease, and key outcomes for community dwelling older adults living with frailty? Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears (...) . the decision to exclude certain disease models, the decision to pool certain units of measurement for an outcome, the choice of effect measure, how subgroup variables are stratified etc. In order to assess the robustness of the findings of the meta-analysis, the analyses are re-run using the alternative options for each decision. If the results of both meta-analyses are similar, the results seem robust. When the conclusions of a meta-analysis significantly change, this should be discussed. Example: To test

2019 PROSPERO

17. Weight change and incidence of cardiovascular disease events among adults with type 2 diabetes

Weight change and incidence of cardiovascular disease events among adults with type 2 diabetes Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external (...) cell dose (linear); blinding of outcome assessment reported (stratified yes vs no). For stratified analyses, a minimum number of 8 studies per subgroup is required. ">Subgroup analyses A sensitivity analysis is conducted to assess the impact of decisions taken in the review process on the meta-analysis outcome. These decisions may have been made in various stages of the review, e.g. the decision to exclude certain disease models, the decision to pool certain units of measurement for an outcome

2019 PROSPERO

18. The paracrine effects of mesenchymal stem cells in cardiovascular disease: a systematic review and meta-analysis of pre-clinical and clinical studies

The paracrine effects of mesenchymal stem cells in cardiovascular disease: a systematic review and meta-analysis of pre-clinical and clinical studies Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content (...) ); sex (stratified per sex); duration of index ischemia (linear); stem cell dose (linear); blinding of outcome assessment reported (stratified yes vs no). For stratified analyses, a minimum number of 8 studies per subgroup is required. ">Subgroup analyses A sensitivity analysis is conducted to assess the impact of decisions taken in the review process on the meta-analysis outcome. These decisions may have been made in various stages of the review, e.g. the decision to exclude certain disease models

2019 PROSPERO

19. The long-term effects of chronic intensive exercise training on cardiovascular disease risk, cardio-metabolic disease and mortality: a systematic review and meta-analysis

The long-term effects of chronic intensive exercise training on cardiovascular disease risk, cardio-metabolic disease and mortality: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability (...) species); sex (stratified per sex); duration of index ischemia (linear); stem cell dose (linear); blinding of outcome assessment reported (stratified yes vs no). For stratified analyses, a minimum number of 8 studies per subgroup is required. ">Subgroup analyses A sensitivity analysis is conducted to assess the impact of decisions taken in the review process on the meta-analysis outcome. These decisions may have been made in various stages of the review, e.g. the decision to exclude certain disease

2019 PROSPERO

20. The implementation of telehealth interventions in the self-management of cardiovascular diseases

The implementation of telehealth interventions in the self-management of cardiovascular diseases Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external (...) cell dose (linear); blinding of outcome assessment reported (stratified yes vs no). For stratified analyses, a minimum number of 8 studies per subgroup is required. ">Subgroup analyses A sensitivity analysis is conducted to assess the impact of decisions taken in the review process on the meta-analysis outcome. These decisions may have been made in various stages of the review, e.g. the decision to exclude certain disease models, the decision to pool certain units of measurement for an outcome

2019 PROSPERO